Ask AI
ProCE Banner Activity

Treatment of Refractory/Resistant CMV in HCT Recipients: Optimizing Transplant Outcomes Through Contemporary CMV Management

Podcast Episodes

There have been major advances in the management of cytomegalovirus (CMV) infection, one of the most significant infectious complications after hematopoietic cell transplant (HCT). In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID, and Marcus Pereira, MD, MPH, FAST, discuss considerations for CMV treatment in HCT recipients and examine treatment options for refractory/resistant CMV.

Released: March 09, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for clinical specialists, including physicians, clinical pharmacists, advanced practice providers, and other healthcare professionals who care for HCT recipients with CMV infections. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Modify antiviral therapy in HCT recipients experiencing treatment-limiting toxicities

  • Optimize antiviral regimens for treatment-refractory CMV infections in post-HCT settings

Faculty Disclosure

Primary Author

Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID: consultant/advisor/speaker: ADMA Biologics, AiCuris, Astellas, Biotest, Gilead, Invivyd, Merck/MSD, Moderna, Pfizer, Shionogi, Symbio, Takeda; researcher: AiCuris, Ansun, Eurofins-Viracor, Genentech, Karius, Merck, OM1, Symbio, Takeda.

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships to disclose.